Jonathan Sheena sold $3.2M of NTRA
director, other at Natera, Inc.. 9,150 shares at an average of $351.49, traded Sep 15, 2026, filed Sep 17, 2026.
Score components
- +15RoleDirector
- +25Trade size$3.2M at market
- 0Share of holdings soldSold 4.0% of holdings
- +15Cluster4 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001646649-26-000032, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Sep 15, 2026 | SOpen-market sale Common Stock10b5-1 | -6,000 | $350.07 | $2.1M | 224,464 | 25 d ago |
| Sep 16, 2026 | SOpen-market sale Common Stock10b5-1 | -200 | $348.03 | $70k | 224,264 | 25 d ago |
| Sep 16, 2026 | SOpen-market sale Common Stock10b5-1 | -100 | $349.05 | $35k | 224,164 | 25 d ago |
| Sep 16, 2026 | SOpen-market sale Common Stock10b5-1 | -1,400 | $353.83 | $495k | 222,764 | 25 d ago |
| Sep 16, 2026 | SOpen-market sale Common Stock10b5-1 | -450 | $354.91 | $160k | 222,314 | 25 d ago |
| Sep 16, 2026 | SOpen-market sale Common Stock10b5-1 | -800 | $355.95 | $285k | 221,514 | 25 d ago |
| Sep 16, 2026 | SOpen-market sale Common Stock10b5-1 | -200 | $356.87 | $71k | 221,314 | 25 d ago |
Related signals
Other insiders at Natera, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 38Weak | Natera, Inc. | Steven Leonard Chapman CEO AND PRESIDENT | $526k 1,273 shares | -1% | |
| 40Moderate | Natera, Inc. | Solomon Moshkevich PRESIDENT, CLINICALDIAGNOSTICS | $1.2M 3,000 shares | -3% | |
| 55Moderate | Natera, Inc. | Jonathan Sheena director, other | $7.0M 18,064 shares | -100% | |
| 40Moderate | Natera, Inc. | Matthew Rabinowitz EXECUTIVE CHAIRMAN | $35M 102,000 shares | -5% | |
| 40Moderate | Natera, Inc. | Matthew Rabinowitz EXECUTIVE CHAIRMAN | $16M 50,000 shares | -2% | |
| 39Weak | Natera, Inc. | Steven Leonard Chapman CEO AND PRESIDENT | $545k 1,698 shares | -2% | |
| 45Moderate | Natera, Inc. | Solomon Moshkevich PRESIDENT, CLINICALDIAGNOSTICS | $5.9M 18,160 shares | -14% | |
| 28Weak | Natera, Inc. | Jonathan Sheena director, other | $2.5M 14,070 shares | -6% | |
| 53Moderate | Natera, Inc. | Matthew Rabinowitz EXECUTIVE CHAIRMAN | $9.0M 50,000 shares | -200% | |
| 43Moderate | Natera, Inc. | Matthew Rabinowitz EXECUTIVE CHAIRMAN | $853k 5,000 shares | -17% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.